Vimarsana
Biggest News Aggregation in the World

Page 49 - Ioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ioscience Today - Breaking & Trending Today

Arix Bioscience PLC: Notification of Major Share Holding - Vimarsana News

Arix Bioscience PLC: Notification of Major Share Holding

DJ Notification of Major Share Holding Arix Bioscience PLC (ARIX) Notification of Major Share Holding 11-Jan-2022 / 17:04 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group.

InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of Amyotrophic Lateral Sclerosis - Vimarsana News

InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of Amyotrophic Lateral Sclerosis

InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of

Satellos Bioscience Inc.: Satellos Bioscience to Participate at Biotech Showcase Virtual 2022 - Vimarsana News

Satellos Bioscience Inc.: Satellos Bioscience to Participate at Biotech Showcase Virtual 2022

Toronto, Ontario--(Newsfile Corp. - January 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change

SK Bioscience to purchase 5 million doses of additional vaccines from Novavax - Vimarsana News

SK Bioscience to purchase 5 million doses of additional vaccines from Novavax

Seoul [South Korea], January 3 (ANI/Global Economic): SK Bioscience signed a contract to pre-purchase up to 5 million doses of Novavax's COVID-19 vaccine 'NVX-CoV2373' in 2022.

Lexaria Bioscience Corp.: Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4 - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

• Dosing is expected to begin by April, 2022KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug